According to numerous worldwide studies, patients with Parkinson’s disease (PD) often experience sleep disturbances, the most common of which are insomnia and excessive daytime sleepiness. The purpose of this study was to determine the quantitative and qualitative profile of sleep disorders in patients with the newly diagnosed PD, stages 1 and 2 according to Hoehn and Yahr. The assessment was carried out using the SCOPA-SLEEP scale. The study involved 95 people: 56 patients with a newly diagnosed PD, who had not previously received treatment (main group), and 39 individuals from the control group. Results. The profile of nocturnal sleep disturbances in PD patients was characterized by various symptoms: difficulty falling asleep (62,5%), night awakening (51,8%), long lying awake (57,1%), early awakening (50,0%), feeling lack of sleep (46,4%). In women, irrespective of the form and stage of PD, disturbances in nighttime sleep were found more often. Daytime hypersomnia among healthy volunteers was observed only in 5 participants (12,8%). The profile of daytime hypersomnia in PD patients was diverse: unexpected falling asleep during the day (n = 15, 26,8%), falling asleep in a calm environment (n = 17, 30,4%) or while reading and watching TV (n = 18, 32,1%). Difficulties in maintaining wakefulness during the day were noted by 13 patients (n = 13, 23,2%) with PD, and 4 patients (7,2%) reported difficulties due to excessive daytime sleepiness. Thus, given the prevalence and profile of dyssomnias, sleep disturbances may be an important sign of PD.

Tourette’s syndrome, the most common cause of tics, manifests itself in a wide range of motor and behavioral disorders and is found in men about three times more often than in women. The purpose — to establish the comorbidity of neuropsychiatric disorders in patients with tic hyperkinesis. Material and methods. The study included 111 patients with tic hyperkinesis of various ages and sex, who were outpatiently observed at the Clinical and Diagnostic Center for Movement Disorders and Botulinum Therapy of the Republic of Tatarstan from 2011 to 2014. Results and conclusions. In the group of patients we studied, tics were more common in males (in 71.6% of cases), and patients with Tourette’s syndrome were numerically predominant, taking into account the visits to the Clinical and Diagnostic Center for Movement Disorders and Botulinum Therapy of the Republic of Tatarstan. Clinical manifestations of obsessive-compulsive disorders were found not only in patients with Tourette’s syndrome, but they are characteristic of 53.2% of patients with tic hyperkinesis of various severity and phenomenology. Also, regardless of the structural and phenomenological characteristics of tic hyperkinesis, they were almost always associated with attention deficit hyperactivity disorder with a predominance of hyperactivity.

No abstract

Amantadine has begun to be used as a possible alternative in therapy to mitigate its effects. There is anecdotal evidence that patients with Parkinson's disease (PD) treated with amantadine and who test positive for COVID-19 often do not develop clinical manifestations of COVID-19. Objective: to compare the clinical course of COVID-19 in patients with PD who took or did not take amantadine sulfate. Patients and methods. A prospective continuous study included 142 patients with PD who were treated in Republican Clinical Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy in Kazan from October 2021 to January 2022. Patients filled out a proprietary internally developed questionnaire.